<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083460</url>
  </required_header>
  <id_info>
    <org_study_id>UARK 2001-37</org_study_id>
    <nct_id>NCT00083460</nct_id>
  </id_info>
  <brief_title>Study of Combination PS-341 and Thalidomide in Multiple Myeloma</brief_title>
  <official_title>UARK 2001-37, A Phase I Exploratory Study of Combination PS-341 and Thalidomide in Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the toxicity of PS-341 combined with one of four doses&#xD;
      of thalidomide in patients with refractory multiple myeloma, and to find the most appropriate&#xD;
      doses of PS-341 and thalidomide in the combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be enrolled in groups of 6-10 patients, each receiving a low dose of PS-341&#xD;
      (1.0 mg/m2) and different dose levels of thalidomide (50, 100, 150, and 200 mg). The first&#xD;
      six patients in each group will receive PS-341 alone for the first cycle, and thalidomide&#xD;
      will be added on day 22. If the combination is found to be safe in these first 6 patients,&#xD;
      the remaining patients in each group will be enrolled. Initially, these patients will receive&#xD;
      PS-341 alone and thalidomide will be added subsequently, if deemed safe based on the first 6&#xD;
      patients in each thalidomide dose cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the toxicity of PS-341 combined with one of four doses of thalidomide in patients with refractory multiple myeloma</measure>
    <time_frame>until pt progresses or unexceptible toxicity</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PS-341</intervention_name>
    <description>Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>A dose of 20mg for cylces 3-8.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of histologically documented multiple myeloma with relapsed or resistant&#xD;
             disease, defined as previously treated with/without autologous stem cell&#xD;
             transplantation and is either relapsing or is resistant after &gt; 1 line of prior&#xD;
             therapy for myeloma&#xD;
&#xD;
          -  Patients can not be eligible for MTRC phase III protocols of higher priority&#xD;
&#xD;
          -  Performance status of greater than or equal to 2 as per SWOG scale&#xD;
&#xD;
          -  Patients must have an absolute neutrophil count &gt; 750/mm3, and a platelet count&#xD;
             greater than or equal to 25,000/mm3&#xD;
&#xD;
          -  No prior malignancy is allowed except for adequately treated basal cell or squamous&#xD;
             cell skin cancer, in situ cervical cancer, or other cancer for which the patient has&#xD;
             been disease free for at least three years. Prior malignancy is acceptable provided&#xD;
             there has been no evidence of disease within the three-year interval&#xD;
&#xD;
          -  Pregnant or nursing women may not participate. Women of childbearing potential must&#xD;
             have a negative pregnancy documented within one week of registration. Women/men of&#xD;
             reproductive potential may not participate unless they have agreed to use an effective&#xD;
             contraceptive method.&#xD;
&#xD;
          -  Male or female adults of at least 18 years of age.&#xD;
&#xD;
          -  Signed written informed consent and willingness to meet follow-up schedule and study&#xD;
             procedure obligations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy or radiotherapy received within the previous 2 weeks&#xD;
&#xD;
          -  Prior Treatment of PS-341&#xD;
&#xD;
          -  Significant neurotoxicity, defined as grade greater than or equal to 2 neurotoxicity&#xD;
             per NCI Common Toxicity Criteria&#xD;
&#xD;
          -  POEMS Syndrome&#xD;
&#xD;
          -  Non-secretory multiple myeloma&#xD;
&#xD;
          -  Active infection requiring antibiotics&#xD;
&#xD;
          -  Clinically significant hepatic dysfunction in the absence of liver metastases as noted&#xD;
             by bilirubin or AST &gt;3 times the upper normal limit or clinically significant&#xD;
             concurrent hepatitis&#xD;
&#xD;
          -  New York Hospital Association (NYHA) Class III or Class IV heart failure&#xD;
&#xD;
          -  Myocardial infarction within the last 6 months&#xD;
&#xD;
          -  Poorly controlled hypertension, diabetes mellitus, or other serious or psychiatric&#xD;
             illness that could potentially interfere with the completion of treatment according to&#xD;
             this protocol&#xD;
&#xD;
          -  Severe renal dysfunction defined as a creatinine clearance &lt; 20 cc/min.&#xD;
&#xD;
          -  Absolute neutrophil count &lt; 750/mm3, and a platelet count &lt; 25,000/mm3&#xD;
&#xD;
          -  Pregnant or potential for pregnancy&#xD;
&#xD;
          -  Breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barlogie Barthel, M.D. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkanas for Medical Sciences website</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences/MIRT</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://myeloma.uams.edu</url>
    <description>Myeloma Institute for Research &amp; Therapy website</description>
  </link>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>May 24, 2004</study_first_submitted>
  <study_first_submitted_qc>May 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2004</study_first_posted>
  <last_update_submitted>July 30, 2010</last_update_submitted>
  <last_update_submitted_qc>July 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Brooke Carter, CRA</name_title>
    <organization>University_Of_Arkansas</organization>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Velcade</keyword>
  <keyword>PS-341</keyword>
  <keyword>Refractory</keyword>
  <keyword>Bortezomid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

